Protection against the Omicron Variant from Previous SARS-CoV-2 Infection

Modern Epidemiology

Rothman, K. J., Greenland, S., & Lash, T. L. (1998) · Cited by 2,096

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Abu-Raddad, L. J., Chemaitelly, H., & Butt, A. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2104974 · Cited by 899

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

Chemaitelly, H., Tang, P., Hasan, M. R., AlMukdad, S., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114114 · Cited by 831

Analysis of matched case-control studies

Pearce, N. E. (2016) · BMJ · doi:10.1136/bmj.i969 · Cited by 774

The test-negative design for estimating influenza vaccine effectiveness

Jackson, M. L., & Nelson, J. C. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.053 · Cited by 510

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

Tang, P., Hasan, M. R., Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., AlMukdad, S., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01583-4 · Cited by 450

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Hasan, M. R., Malek, J. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01446-y · Cited by 386

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

(2021) · doi:10.1016/j.eclinm.2021.100861 · Cited by 201

Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting

Abu-Raddad, L. J., Chemaitelly, H. S., Malek, J. A., Ahmed, A. A., Mohamoud, Y. A., Younuskunju, S., Ayoub, H. H., Kanaani, Z. A., Al‐Khal, A., Al‐Kuwari, E., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1846 · Cited by 176

COVID-19 (SARS-CoV-2) outbreak monitoring using wastewater-based epidemiology in Qatar

Saththasivam, J., El-Malah, S. S., Gomez, T., Jabbar, K. A., Remanan, R., Krishnankutty, A. K., Ogunbiyi, O. O., Rasool, K., Ashhab, S., Rashkeev, S. N., et al. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.145608 · Cited by 150

Risk and protective factors for SARS-CoV-2 reinfections, surveillance data, Italy, August 2021 to March 2022

Sacco, C., Petrone, D., Manso, M. D., Mateo‐Urdiales, A., Fabiani, M., Bressi, M., Bella, A., Pezzotti, P., Rota, M. C., Riccardo, F., et al. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.20.2200372 · Cited by 29

Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention

Xu, A., Hong, B., Lou, F., Wang, S., Li, W., Shafqat, A., An, X., Zhao, Y., Song, L., Tong, Y., et al. (2022) · MedComm · doi:10.1002/mco2.172 · Cited by 30

CD8+ T-cell immune escape by SARS-CoV-2 variants of concern

Kombe, A. J. K., Biteghe, F. A. N., Ndoutoume, Z. N., & Jin, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.962079 · Cited by 29

Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study

Zheng, H. X., Cao, Y., Chen, X., Wang, F., Hu, Y., Song, W., Chai, Y., Gu, Q., Shi, Y., Feng, Y., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00674-2 · Cited by 27

Coronavirus Disease 2019 Vaccine Boosting in Previously Infected or Vaccinated Individuals

Shrestha, N. K. M., Shrestha, P., Burke, P. C., Nowacki, A. S., Terpeluk, P., & Gordon, S. M. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac327 · Cited by 27

Protection of vaccination versus hybrid immunity against infection with COVID-19 Omicron variants among Health-Care Workers

Ntziora, F., Kostaki, E. G., Karapanou, Α., Mylona, M., Tseti, I. K., Sipsas, N. V., Paraskevis, D. N., & Sfikakis, P. P. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.09.042 · Cited by 29

Comparing hybrid and regular COVID-19 vaccine-induced immunity against the Omicron epidemic

Huang, L., Lai, F. T. T., Yan, V. K. C., Cheng, F. W. T., Cheung, C. L., Chui, C. S. L., Li, X., Wan, E. Y. F., Wong, C. K. H., Hung, I. F., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00594-7 · Cited by 30

Assessing healthy vaccinee effect in COVID-19 vaccine effectiveness studies: a national cohort study in Qatar

Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · eLife · doi:10.7554/elife.103690 · Cited by 26

Long-term Protection Associated With COVID-19 Vaccination and Prior Infection

Tenforde, M. W., Link‐Gelles, R., & Patel, M. M. (2022) · JAMA · doi:10.1001/jama.2022.14660 · Cited by 26

Turning point in COVID-19 severity and fatality during the pandemic: a national cohort study in Qatar

Chemaitelly, H. S., Ayoub, H. H., Faust, J. S., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Thani, A. A. A., Kanaani, Z. A., et al. (2023) · BMJ Public Health · doi:10.1136/bmjph-2023-000479 · Cited by 26

COVID reinfections surge during Omicron onslaught

Mallapaty, S. (2022) · Nature · doi:10.1038/d41586-022-00438-3 · Cited by 26

Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland—A multicentre cohort study

Flury, B. B., Güsewell, S., Egger, T., Leal-Neto, O. B., Brucher, A., Lemmenmeier, E., Kleeb, D. M., Möller, J. C., Rieder, P., Ruetti, M., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1004125 · Cited by 25

Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review

Arabi, M., Al-Najjar, Y. A., Sharma, O., Kamal, I., Javed, A., Gohil, H., Paul, P., Al-Khalifa, A. M., Laws, S., & Zakaria, D. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08328-3 · Cited by 25

An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution

Subissi, L., Otieno, J. R., Worp, N., Cohen, H. A., Munnink, B. B. O., Abu-Raddad, L. J., Alm, E., Barakat, A., Barclay, W., Bhiman, J. N., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02949-0 · Cited by 25

Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infection—Final Update of a Living, Rapid Review

Holmer, H. K., Mackey, K., Fiordalisi, C. V., & Helfand, M. (2022) · Annals of Internal Medicine · doi:10.7326/m22-1745 · Cited by 24

The disproportionate case–fatality ratio of COVID-19 between countries with the highest vaccination rates and the rest of the world

Haider, N., Hasan, M. N., Guitián, J., Khan, R. A., McCoy, D., Ntoumi, F., Dar, O. A., Ansumana, R., Uddin, M. J., Zumla, A. I., et al. (2023) · IJID Regions · doi:10.1016/j.ijregi.2023.01.011 · Cited by 24

Research progress in spike mutations of SARS‐CoV‐2 variants and vaccine development

He, X., He, C., Hong, W., Yang, H. J., & Wei, X. (2023) · Medicinal Research Reviews · doi:10.1002/med.21941 · Cited by 25

Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation

Gazit, S., Saciuk, Y., Perez, G., Peretz, A., Ben‐Tov, A., Stuart, E. A., & Patalon, T. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00103-9 · Cited by 25

Vaccines against SARS-CoV-2 variants and future pandemics

Park, T., Hwang, H., Moon, S., Kang, S. G., Song, S., Kim, Y. H., Kim, H., Ko, E., Yoon, S., Kang, S., et al. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2110075 · Cited by 23

Omicron Sub-Lineage BA.5 Infection Causes Attenuated Pathology and Results in Robust Protection in Omicron Recovered hACE2 Transgenic Mice

Rizvi, Z. A., Dandotiya, J., Sadhu, S., Khatri, R., Singh, J., Singh, V., Adhikari, N., Sharma, K., Das, V., Pandey, A. K., et al. (2022) · Communications Biology · doi:10.1038/s42003-023-05263-6 · Cited by 23

Impact of Prior COVID-19 Immunization and/or Prior Infection on Immune Responses and Clinical Outcomes

Livieratos, A., Gogos, C. A., & Akinosoglou, K. (2024) · Viruses · doi:10.3390/v16050685 · Cited by 23

Epidemiological assessment of SARS-CoV-2 reinfection

Almadhi, M. A., Alsayyad, A., Conroy, R. M., Atkin, S. L., AlAwadhi, A. I., Al‐Tawfiq, J. A., & AlQahtani, M. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.07.075 · Cited by 23

Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection

Khatamzas, E., Antwerpen, M. H., Rehn, A., Graf, A., Hellmuth, J. C., Hollaus, A., Mohr, A., Gaitzsch, E., Weiglein, T., Georgi, E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32772-5 · Cited by 22

At-home sampling to meet geographical challenges for serological assessment of SARS-CoV-2 exposure in a rural region of northern Sweden, March to May 2021: a retrospective cohort study

Byström, J. W., Vikström, L., Rosendal, E., Gröning, R., Gwon, Y.-D., Nilsson, E., Sharma, A., Espaillat, A., Hanke, L., McInerney, G. M., et al. (2023) · Eurosurveillance · doi:10.2807/1560-7917.es.2023.28.13.2200432 · Cited by 22

A chronological review of COVID-19 case fatality rate and its secular trend and investigation of all-cause mortality and hospitalization during the Delta and Omicron waves in the United States: a retrospective cohort study

Li, J., Liao, P., Wei, J. C., Hsu, S., & Yeh, C. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1143650 · Cited by 22

The Anti-SARS-CoV-2 IgG1 and IgG3 Antibody Isotypes with Limited Neutralizing Capacity against Omicron Elicited in a Latin Population a Switch toward IgG4 after Multiple Doses with the mRNA Pfizer–BioNTech Vaccine

Espino, A. M., Armina-Rodríguez, A., Alvarez, L., Ocasio‐Malavé, C., Ramos-Nieves, R., Rodríguez-Martinó, E., López-Marte, P., Torres, E. A., & Sariol, C. A. (2024) · Viruses · doi:10.3390/v16020187 · Cited by 23

Vaccine-Acquired SARS-CoV-2 Immunity versus Infection-Acquired Immunity: A Comparison of Three COVID-19 Vaccines

Samanovic, M. I., Oom, A. L., Cornelius, A. R., Gray-Gaillard, S. L., Karmacharya, T., Tuen, M., Wilson, J. P., Tasissa, M., Goins, S., Herati, R. S., et al. (2022) · Vaccines · doi:10.3390/vaccines10122152 · Cited by 21

Early Omicron infection is associated with increased reinfection risk in older adults in long-term care and retirement facilities

Breznik, J. A., Rahim, A., Zhang, A., Ang, J. C., Stacey, H. D., Bhakta, H., Clare, R., Liu, L., Kennedy, A. E., Hagerman, M., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102148 · Cited by 21

Risk of COVID-19 after natural infection or vaccination

Rick, A.-M., Laurens, M. B., Huang, Y., Yu, C., Martin, T., Rodriguez, C. A., Rostad, C. A., Maboa, R., Baden, L. R., Sahly, H. M. E., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104799 · Cited by 21

Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant

Chemaitelly, H. S., Coyle, P. V., Kacem, M. A. B. H., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2024) · Journal of Travel Medicine · doi:10.1093/jtm/taae053 · Cited by 21

Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK)

Vivaldi, G., Jolliffe, D. A., Holt, H., Tydeman, F. A. S., Talaei, M., Davies, G. A., Lyons, R. A., Griffiths, C., Kee, F., Sheikh, A., et al. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100501 · Cited by 21

SARS-CoV-2 IgG seropositivity after the severe Omicron wave of COVID-19 in Hong Kong

Poon, R. W.-S., Chan, B. P.-C., Chan, W.-M., Fong, C. H.-Y., Zhang, X., Lu, L., Chen, L.-L., Lam, J.-Y., Cheng, V. C.-C., Wong, S. S. Y., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2106899 · Cited by 20

Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response

Giambra, V., Piazzolla, V., Cocomazzi, G., Squillante, M. M., Santis, E. D., Totti, B., Cavorsi, C., Giuliani, F., Serra, N., & Mangia, A. (2022) · Vaccines · doi:10.3390/vaccines10081281 · Cited by 20

Curcumin Confers Anti-Inflammatory Effects in Adults Who Recovered from COVID-19 and Were Subsequently Vaccinated: A Randomized Controlled Trial

Fessler, S. N., Chang, Y., Liu, L., & Johnston, C. S. (2023) · Nutrients · doi:10.3390/nu15071548 · Cited by 19

Comparative epidemic expansion of SARS-CoV-2 variants Delta and Omicron in the Brazilian State of Amazonas

Arantes, I., Bello, G., do Nascimento, V. A., de Souza, V. C., da Silva, A., Silva, D., Nascimento, F., Mejía, M., Brandão, M. J., Gonçalves, L. M. F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37541-6 · Cited by 21

Distinguishing SARS-CoV-2 infection and vaccine responses up to 18 months post-infection using nucleocapsid protein and receptor-binding domain antibodies

Jarlhelt, I., Pérez‐Alós, L., Bayarri‐Olmos, R., Hansen, C. B., Petersen, M. S., Weihe, P., Armenteros, J. J. A., Madsen, J. R., Nielsen, J. P. S., Hilsted, L. M., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01796-23 · Cited by 20

Effectiveness of two and three mRNA COVID‐19 vaccine doses against Omicron‐ and Delta‐Related outpatient illness among adults, October 2021–February 2022

Kim, S. S., Chung, J. R., Talbot, H. K., Grijalva, C. G., Wernli, K. J., Kiniry, E. L., Martin, E. T., Monto, A. S., Belongia, E. A., McLean, H. Q., et al. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13029 · Cited by 22

COVID‐19 vaccinations and rates of infections, hospitalizations, ICU admissions, and deaths in Europe during SARS‐CoV‐2 Omicron wave in the first quarter of 2022

Rzymski, P., Kasianchuk, N., Sikora, D., & Poniedziałek, B. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28131 · Cited by 19

Competition of SARS-CoV-2 variants on the pandemic transmission dynamics

Chen, J., Gu, C., Ruan, Z., & Tang, M. (2023) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2023.113193 · Cited by 19

Prior SARS‐CoV‐2 infection and COVID‐19 vaccine effectiveness against outpatient illness during widespread circulation of SARS‐CoV‐2 Omicron variant, US Flu VE network

Tartof, S. Y., Xie, F., Yadav, R., Wernli, K. J., Martin, E. T., Belongia, E. A., Gaglani, M., Zimmerman, R. K., Talbot, H. K., Thornburg, N. J., et al. (2023) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13143 · Cited by 20

Modelling herd immunity requirements in Queensland: impact of vaccination effectiveness, hesitancy and variants of SARS-CoV-2

Sanz‐Leon, P., Hamilton, L. H. W., Raison, S. J., Pan, A. J. X., Stevenson, N. J., Stuart, R. M., Abeysuriya, R., Kerr, C. C., Lambert, S. B., & Roberts, J. A. (2022) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2021.0311 · Cited by 18

A COVID-19 model incorporating variants, vaccination, waning immunity, and population behavior

LaJoie, Z., Usherwood, T. R., Sampath, S. G., & Srivastava, V. (2022) · Scientific Reports · doi:10.1038/s41598-022-24967-z · Cited by 20

Low-sugar universal mRNA vaccine against coronavirus variants with deletion of glycosites in the S2 or stem of SARS-CoV-2 spike messenger RNA (mRNA)

Cheng, C.-W., Wu, C., Wang, S.-W., Chen, J., Kung, C., Liao, K., & Wong, C. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314392120 · Cited by 18

Long-term monitoring of SARS-CoV-2 seroprevalence and variants in Ethiopia provides prediction for immunity and cross-immunity

Merkt, S., Ali, S., Gudina, E. K., Adissu, W., Gize, A., Muenchhoff, M., Graf, A., Krebs, S., Elsbernd, K., Kisch, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47556-2 · Cited by 18

Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model

Johnson, D. M., Brasel, T., Massey, S., Garron, T. M., Grimes, M., Smith, J. N., Torres, M., Wallace, S. M., Tezanos, A. G. V., Beasley, D. W. C., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105492 · Cited by 18

Prior exposure to pathogens augments host heterogeneity in susceptibility and has key epidemiological consequences

Hawley, D. M., Pérez‐Umphrey, A. A., Adelman, J. S., Fleming-Davies, A. E., Garrett-Larsen, J., Geary, S. J., Childs, L. M., & Langwig, K. E. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012092 · Cited by 18

Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline Workers

Ellingson, K., Hollister, J., Porter, C., Khan, S. R., Feldstein, L. R., Naleway, A. L., Gaglani, M., Caban-Martinez, A. J., Tyner, H. L., Lowe, A. A., et al. (2023) · Emerging infectious diseases · doi:10.3201/eid2903.221314 · Cited by 17

The impact of COVID-19 on primary health care services in Qatar: 2 years of response and coping 2020-2021

Al‐Kuwari, M. G., Bakri, A. H., Kandy, M. C., Gibb, J. M., Abdulla, M. Y., Abdulla, S. A. A., & Abdulmalik, M. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1259_22 · Cited by 17

Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022

Hall, V. J., Insalata, F., Foulkes, S., Kirwan, P., Sparkes, D., Atti, A., Cole, M. J., Lacy, E. D., Price, L., Corrigan, D., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.10.022 · Cited by 18

Association between vaccination rates and COVID-19 health outcomes in the United States: a population-level statistical analysis

Du, H., Saiyed, S., & Gardner, L. (2024) · BMC Public Health · doi:10.1186/s12889-024-17790-w · Cited by 18

Addressing bias in the definition of SARS-CoV-2 reinfection: implications for underestimation

Chemaitelly, H. S., Ayoub, H. H., Tang, P., Yassine, H. M., Thani, A. A. A., Hasan, M. R., Coyle, P. V., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1363045 · Cited by 17

Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient

Sukik, L., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Yassine, H. M., Thani, A. A. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.026 · Cited by 17

New SARS-CoV-2 Omicron variant — clinical picture, treatment, prevention (literature review)

Vechorko, V. I., Валерьевич, А. О., & Зимин, А. А. (2022) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2022-3228 · Cited by 17

Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern

Chaouat, A. E., Brizić, I., Brlić, P. K., Atari, N., Kliker, L., Alfi, O., Mandelboim, M., Wolf, D. G., Tafish, L., Kol, I., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104935 · Cited by 17

Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections

Qassim, S. H., Hasan, M. R., Tang, P., Chemaitelly, H. S., Ayoub, H. H., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Rahim, H. F. A., Nasrallah, G. K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.984784 · Cited by 19

There is nothing exempt from the peril of mutation – The Omicron spike

Behl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Anwer, M. K., Makeen, H. A., Albratty, M., Alhazmi, H. A., Bhatia, S., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112756 · Cited by 16

Preliminary Study of the Protectiveness of Vaccination Against the COVID-19 in the Outbreak of VOC Omicron BA.2 - Jilin City, Jilin Province, China, March 3-April 12, 2022.

Fan, X., Lü, S., Bai, L., Liu, H., Fu, J., Jin, X., He, Y., Lu, J., & Dong, X. (2022) · PubMed Central · doi:10.46234/ccdcw2022.081 · Cited by 16

SARS-CoV-2 Spike and Nucleocapsid Antibody Response in Vaccinated Croatian Healthcare Workers and Infected Hospitalized Patients: A Single Center Cohort Study

Brlić, P. K., Pavletić, M., Lerga, M., Krstanović, F., Matešić, M. P., Miklić, K., Malić, S., Mikša, L., Pajcur, M., Peruč, D., et al. (2022) · Viruses · doi:10.3390/v14091966 · Cited by 17

Impact of Vaccination, Prior Infection, and Therapy on Omicron Infection and Mortality

Wang, X., Zein, J., Ji, X., & Lin, D.-Y. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac460 · Cited by 17

The impact of cross-reactive immunity on the emergence of SARS-CoV-2 variants

Thompson, R. N., Southall, E., Daon, Y., Lovell-Read, F. A., Iwami, S., Thompson, C., & Obolski, U. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1049458 · Cited by 16

Rapid SARS-CoV-2 Variants Enzymatic Detection (SAVED) by CRISPR-Cas12a

Yang, J., Barua, N., Rahman, M. N., Li, C., Lo, N. W. S., Yeong, K.-Y., Tsang, T. F., Yang, X., Cheung, Y., Tsang, A. K. L., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.03260-22 · Cited by 15

A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses

Torresi, J., Edeling, M. A., Nolan, T. M., & Godfrey, D. I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.914167 · Cited by 15

High titre neutralizing antibodies in response to SARS–CoV–2 infection require RBD–specific CD4 T cells that include proliferative memory cells

Phetsouphanh, C., Khoo, W. H., Jackson, K., Klemm, V., Howe, A., Aggarwal, A., Akerman, A., Milogiannakis, V., Stella, A. O., Rouet, R., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032911 · Cited by 15

The Cold-Adapted, Temperature-Sensitive SARS-CoV-2 Strain TS11 Is Attenuated in Syrian Hamsters and a Candidate Attenuated Vaccine

Xu, J., Liu, M., Niu, X., Hanson, J., Jung, K., Ru, P., Tu, H., Jones, D. M., Vlasova, A. N., Saif, L. J., et al. (2022) · Viruses · doi:10.3390/v15010095 · Cited by 16

The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice

Miteva, D., Kitanova, M., Batselova, H., Lazova, S., Chervenkov, L., Peshevska-Sekulovska, M., Sekulovski, M., Gulinac, M., Vasilev, G., Tomov, L., et al. (2023) · Vaccines · doi:10.3390/vaccines11071181 · Cited by 16

Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023

Cai, J., Zhang, H. C., Zhu, K., Zhu, F., Wang, Y., Wang, S., Xie, F., Zhang, M., Rui, L., Li, S., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2292071 · Cited by 15

Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi

Mseka, U. L., Mandolo, J. J., Nyoni, K., Divala, O., Kambalame, D. M., Mapemba, D., Kamzati, M., Chibwe, I., Henrion, M., Manda, K., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101800 · Cited by 14

SARS-CoV-2 reinfections during the first three major COVID-19 waves in Bulgaria

Marinov, G. K., Mladenov, M., Rangachev, A., & Alexiev, I. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274509 · Cited by 14

Neutralizing antibody responses in patients hospitalized with SARS-CoV-2 Delta or Omicron infection

Linderman, S. L., Lai, L., Gamarra, E. L. B., Lau, M. S. Y., Edupuganti, S., Surie, D., Tenforde, M. W., Chappell, J. D., Mohr, N. M., Gibbs, K. W., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci164303 · Cited by 14

Time-dependent risk of COVID-19 death with overwhelmed health-care capacity in Japan, 2020–2022

Hayashi, K., & Nishiura, H. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07929-8 · Cited by 14

COVID-19 Vaccine Hesitancy Among Patients Recovered From COVID-19 Infection in Wuhan, China: Cross-Sectional Questionnaire Study

Huang, Y., Zhang, L., Fu, J., Wu, Y., Wang, H., Xiao, W., Xin, Y., Dai, Z., Si, M., Chen, X., et al. (2023) · JMIR Public Health and Surveillance · doi:10.2196/42958 · Cited by 15

Omicron breakthrough infections in vaccinated or previously infected hamsters

Zhou, J., Sukhova, K., McKay, P. F., Kurshan, A., Yau, Y., Lechmere, T., Brown, J. C., Moshe, M., Kugathasan, R., Snell, L. B., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2308655120 · Cited by 15

Protection Against the Omicron Variant Offered by Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Retrospective Cohort Study

Rothberg, M. B., Kim, P., Shrestha, N. K. M., Kojima, L., & Tereshchenko, L. G. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac604 · Cited by 13

COVID-19 Modeling Outcome versus Reality in Sweden

Carlsson, M., & Söderberg‐Nauclér, C. (2022) · Viruses · doi:10.3390/v14081840 · Cited by 13

Effect of Previous COVID-19 Vaccination on Humoral Immunity 3 Months after SARS-CoV-2 Omicron Infection and Booster Effect of a Fourth COVID-19 Vaccination 2 Months after SARS-CoV-2 Omicron Infection

Kim, J., Seo, H., Kim, H.-W., Kim, D., Kwon, H., & Kim, Y.-K. (2022) · Viruses · doi:10.3390/v14112458 · Cited by 13

Dynamics of Naturally Acquired Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 in Children and Adolescents

Patalon, T., Saciuk, Y., Hadad, H. O., Peretz, A., Peretz, A., Ben‐Tov, A., & Gazit, S. (2023) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2023.02.016 · Cited by 13

Risk of SARS-CoV-2 Reinfection by Vaccination Status, Predominant Variant, and Time from Previous Infection: A Cohort Study in Italy

Vicentini, M., Venturelli, F., Mancuso, P., Bisaccia, E., Zerbini, A., Massari, M., Cossarizza, A., Biasi, S. D., Pezzotti, P., Bedeschi, E., et al. (2022) · Eurosurveillance · doi:10.2139/ssrn.4132329 · Cited by 13

Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters

Port, J. R., Yinda, C. K., Riopelle, J. C., Weishampel, Z. A., Saturday, T. A., Avanzato, V. A., Schulz, J. E., Holbrook, M. G., Barbian, K., Perry-Gottschalk, R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42346-8 · Cited by 13

How Did the COVID-19 Pandemic Affect Population Mobility in Taiwan?

Liu, S., Chang, H.-C., Liu, J.-F., & Kuo, H. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191710559 · Cited by 13

An international observational study to assess the impact of the Omicron variant emergence on the clinical epidemiology of COVID-19 in hospitalised patients

Gonçalves, B. P., Hall, M. D., Jassat, W., Balan, V., Murthy, S., Kartsonaki, C., Semple, M. G., Rojek, A. M., Baruch, J., Reyes, L. F., et al. (2022) · eLife · doi:10.7554/elife.80556 · Cited by 12

Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone

da Silva, E. S., Kohnen, M., Gilson, G., Staub, T., Arendt, V., Hilger, C., Servais, J.-Y., Charpentier, É., Domingues, O., Snoeck, C. J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147675 · Cited by 12

Significant Rise in SARS-CoV-2 Reinfection Rate in Vaccinated Hospital Workers during the Omicron Wave: A Prospective Cohort Study

Ochoa‐Hein, E., Leal-Morán, P. E., Nava-Guzmán, K. A., Vargas-Fernández, A. T., Vargas-Fernández, J. F., Díaz-Rodríguez, F., Rayas-Bernal, J. A., González-González, R., Vázquez-González, P., Huertas-Jiménez, M. A., et al. (2022) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.22000159 · Cited by 12

SARS-CoV-2 Seroprevalence and Cross-Variant Antibody Neutralization in Cats, United Kingdom

Tyson, G. B., Jones, S., Logan, N., McDonald, M., Marshall, L., Murcia, P. R., Willett, B. J., Weir, W., & Hosie, M. J. (2023) · Emerging infectious diseases · doi:10.3201/eid2906.221755 · Cited by 12

Enhancing global preparedness during an ongoing pandemic from partial and noisy data

Klamser, P., d’Andrea, V., Lauro, F. D., Zachariae, A., Bontorin, S., Nardo, A. D., Hall, M. D., Maier, B. F., Luca Ferretti, A., Brockmann, D., et al. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad192 · Cited by 13

SARS‐CoV‐2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study

Mahmoud, M., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2023) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13224 · Cited by 12

Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial

Chew, C. K., Wang, R., Bavanandan, S., Zainudin, N., Zhao, X., Ahmed, S., Nair, D., Hou, L., Yahya, R., Ch’ng, S. S., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-01003-x · Cited by 11

Strength and durability of indirect protection against SARS-CoV-2 infection through vaccine and infection-acquired immunity

Tan, S. T., Rodríguez-Barraquer, I., Kwan, A. T., Blumberg, S., Park, H. J., Hutchinson, J., Leidner, D., Lewnard, J. A., Sears, D., & Lo, N. C. (2025) · Nature Communications · doi:10.1038/s41467-024-55029-9 · Cited by 12

An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19

Soleimanian, S., Alyasin, S. S., Sepahi, N., Ghahramani, Z., Kanannejad, Z., Yaghobi, R., & Karimi, M. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884879 · Cited by 11

Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Residents of US Nursing Homes Before and During the Delta Variant Predominance, December 2020–November 2021

Hatfield, K. M., Baggs, J. M., Wolford, H. M., Fang, M., Sattar, A. A., Montgomery, K. S., Jin, S., Jernigan, J. A., & Pilishvili, T. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac562 · Cited by 12

SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants

Kubale, J., Gleason, C., Carreño, J. M., Srivastava, K., Singh, G., PARIS Study Team, Gordon, A., Krammer, F., Simon, V. R., Alshammary, H., et al. (2022) · mBio · doi:10.1128/mbio.01784-22 · Cited by 12

Evaluating methodological approaches to assess the severity of infection with SARS-CoV-2 variants: scoping review and applications on Belgian COVID-19 data

Meurisse, M., Oyen, H. J. V., Blot, K. Y., Catteau, L., Serrien, B., Klamer, S., Cauët, É., Robert, A. R., & Goethem, N. V. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07777-6 · Cited by 11

Exercise mobilizes diverse antigen specific T-cells and elevates neutralizing antibodies in humans with natural immunity to SARS CoV-2

Baker, F. L., Zúñiga, T. M., Smith, K. A., Batatinha, H., Kulangara, T. S., Seckeler, M. D., Burgess, S. C., Katsanis, E., & Simpson, R. J. (2023) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2023.100600 · Cited by 13

Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19–Associated Encounters in Adults During Delta and Omicron Predominance

Bozio, C. H., Butterfield, K. A., Hagen, M. B., Grannis, S. J., Drawz, P. E., Hartmann, E., Ong, T. C., FIREMAN, B. H., Natarajan, K., Dascomb, K. K., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad040 · Cited by 11

Increased vaccine sensitivity of an emerging SARS-CoV-2 variant

Lewnard, J. A., Hong, V. X., Kim, J. S., Shaw, S. F., Lewin, B. J., Takhar, H. S., Lipsitch, M., & Tartof, S. Y. (2023) · Nature Communications · doi:10.1038/s41467-023-39567-2 · Cited by 11

Risk of SARS-CoV-2 infection and hospitalization in individuals with natural, vaccine-induced and hybrid immunity: a retrospective population-based cohort study from Estonia

Uusküla, A., Pisarev, H., Tisler, A., Meister, T., Suija, K., Huik, K., Abroi, A., Kalda, R., Kolde, R., & Fischer, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-47043-6 · Cited by 11

A SARS-CoV-2: Companion Animal Transmission and Variants Classification

Pandit, R., & Matthews, Q. L. (2023) · Pathogens · doi:10.3390/pathogens12060775 · Cited by 11

Differences in virus and immune dynamics for SARS-CoV-2 Delta and Omicron infections by age and vaccination histories

Tan, M. W., Anelone, A. J. N., Tay, A. T., Tan, R. Y., Zeng, K., Tan, K. B., & Clapham, H. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09572-x · Cited by 10

Transient and durable T cell reactivity after COVID-19

Martner, A., Wiktorin, H. G., Törnell, A., Ringlander, J., Arabpour, M., Lindh, M., Lagging, M., Nilsson, S., & Hellstrand, K. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2203659119 · Cited by 10

Outcomes associated with SARS-CoV-2 reinfection in individuals with natural and hybrid immunity

Suleyman, G., Fadel, R. A., Patel, K., Shadid, A. M., Stuart, H. B. C., Kattula, M., Janis, A., Maki, M., Chao, S., Alangaden, G. J., et al. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.06.003 · Cited by 10

Frequency and risk of SARS-CoV-2 reinfections in Norway: a nation-wide study, February 2020 to January 2022

Bøås, H., Storm, M. L., Tapia, G., Kristoffersen, A. B., Løvlie, A. L., Størdal, K., Lyngstad, T. M., Bragstad, K., Hungnes, O., & Veneti, L. (2024) · BMC Public Health · doi:10.1186/s12889-024-17695-8 · Cited by 10

Immunity Acquired From the First Wave of COVID-19 Against Reinfections Up to Omicron Predominance

Lan, F., Kasteler, S. D., Sidossis, A. C., Iliaki, E. F., Buley, J., Nathan, N., Osgood, R. A., Bruno‐Murtha, L. A., & Kales, S. N. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.11.002

P-1948. Differential Patterns of Protection from Natural Infection against SARS-CoV-2 Reinfection in the Pre-Omicron and Omicron Eras

Chemaitelly, H. S., Ayoub, H. H., & Abu-Raddad, L. J. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae631.2107

Protection Against the Omicron Variant Offered by Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Retrospective Cohort Study

Rothberg, M. B., Kim, P., Shrestha, N. K. M., Kojima, L., & Tereshchenko, L. G. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac604 · Cited by 13

Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA–Vaccinated and Nonvaccinated Individuals in Quebec, Canada

Carazo, S., Skowronski, D. M., Brisson, M., Sauvageau, C., Brousseau, N., Gilca, R., Ouakki, M., Barkati, S., Fafard, J., Talbot, D. C., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.36670 · Cited by 48

Protection of Prior SARS-CoV-2 Infection Against Different Variants, Including Omicron Descendants, in a Country with High Viral Transmission

Escobar-Agreda, S., Araujo-Castillo, R. V., Pampa-Espinoza, L., Valencia, J. S., & Solari, L. (2025) · Pathogens and Immunity · doi:10.20411/pai.v10i2.760